| Autor: |
Ghafari S; Vira Vigene research institute, Tehran, Iran., Komeilian M; Vira Vigene research institute, Tehran, Iran., Hashemi MS; Vira Vigene research institute, Tehran, Iran., Oushani S; Vira Vigene research institute, Tehran, Iran., Rigi G; Department of Biology, Faculty of Science, Behbahan Khatam Alanbia University of Technology, Behbahan, Iran., Rashidieh B; Vira Vigene research institute, Tehran, Iran., Yarahmadi K; Vira Vigene research institute, Tehran, Iran., Khoddam F; Vira Vigene research institute, Tehran, Iran. |
| Abstrakt: |
Listeriolysine-O (LLO) is a 50KDa protein responsible for Listeria monocytogenes pathogenicity. The structure of LLO (PDB ID: 4CDB) with domains D1 to D4 is known. Therefore, it is of interest to identify conserved regions among LLO variants for destabilizing oligomerization (50 mer complex) of its monomers using appropriate inhibitors. Therefore, it is of interest to identify suitable inhibitors for inhibiting LLO. Previous reports suggest the use of flavanoids like compounds for inhibiting LLO. Our interest is to identify improved compounds to destabilize LLO oligomerization. We used a library (Zinc database) containing 200,000 drug-like compounds against LLO using molecular docking based screening. This resulted in five hits that were further analyzed for pharmacological properties. The hit #1 (2-methyloctadecane- 1, 3, 4-triol) was further refined using appropriate modifications for creating a suitable pharmacophore model LLO inhibition. The modified compound (1-(4-Cyclopent-3-enyl-6, 7-dihydroxy-8-hydroxymethyl-nona-2, 8-dienylideneamino)-penta-1,4-dien-3-one) shows fitting binding properties with LLO with no undesirable pharmacological properties such as toxicity. |
